Cannabis and Cannabinoid Research
June 17, 2024
Madeline K Stanger, Harmony O Soffer, Angela D Bryan et al.
1 citation
Among regular cannabis users in Colorado, those who had also used psilocybin in the past three months reported higher cannabis dependence scores and more strongly endorsed using cannabis for enjoyment, boredom, and altered experience than those who had not used psilocybin recently. The correlation between cannabis dependence and the motive of altered experience was stronger for co-users. The findings suggest motivational differences and potentially greater risk of harm for people who co-use cannabis and psilocybin.
Human psychopharmacology
September 1, 2025
Renée Martin-Willett, Carillon J Skrzynski, Angela D Bryan et al.
In a randomized trial, people using cannabis with cannabidiol (CBD) experienced greater decreases in symptoms of depression, anxiety, and stress over four weeks compared to those using cannabis with tetrahydrocannabinol (THC). This benefit was most pronounced among participants who reported average or high levels of perceived discrimination. No significant changes in drinking behaviors were observed. The findings suggest that CBD may help reduce negative emotional symptoms in the short term without increasing risk for alcohol misuse, and that perceived discrimination plays an important role in this relationship.
Cannabis and cannabinoid research
February 1, 2024
Laurel P Gibson, Raeghan L Mueller, Evan A Winiger et al.
Regular cannabis users who self-administered commercially available edible products experienced increased intoxication and elation, decreased tension, and no change in paranoia two hours after use. Those who consumed a CBD-dominant product reported less intoxication than those who used a THC-only or THC+CBD product. Participants who used a THC+CBD product consumed less THC and had lower plasma THC levels than those using a THC-only product, yet reported similar positive and psychotomimetic effects. Psychotomimetic effects were very low across all conditions. The findings suggest that edible products containing CBD may allow experienced users to achieve desired effects with lower THC exposure, potentially reducing harm.
Addiction biology
January 1, 2022
Laurel P Gibson, Hollis C Karoly, Jarrod M Ellingson et al.
Cannabis flower with both THC and CBD produces similar positive effects but less paranoia and anxiety than THC-dominant cannabis. In a naturalistic at-home study, 159 regular cannabis users were randomly assigned to one of three chemovars: THC-dominant (24% THC, 1% CBD), THC+CBD (9% THC, 10% CBD), or CBD-dominant (1% THC, 23% CBD). Plasma samples showed those using the CBD-dominant or THC+CBD chemovars had significantly less THC and more CBD than those using the THC-dominant chemovar. The THC+CBD chemovar yielded similar positive subjective effects but significantly less paranoia and anxiety compared to the THC-dominant chemovar, suggesting potential harm reduction from CBD.